Anticancer research最新文献

Evaluation of the Therapeutic Potential of DPP4 Inhibitor in Upper Tract Urothelial Carcinoma Cells.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17487

Hao-Lun Luo, Yen-Ting Wu, Yi-Yang Liu, Hui-Ying Liu, Yin-Lun Chang

{"title":"Evaluation of the Therapeutic Potential of DPP4 Inhibitor in Upper Tract Urothelial Carcinoma Cells.","authors":"Hao-Lun Luo, Yen-Ting Wu, Yi-Yang Liu, Hui-Ying Liu, Yin-Lun Chang","doi":"10.21873/anticanres.17487","DOIUrl":"https://doi.org/10.21873/anticanres.17487","url":null,"abstract":"Background/aim: Dipeptidyl peptidase-4 (DPP4) inhibitors like sitagliptin are recognized for their therapeutic role in diabetes. Elevated levels of DPP4 are strongly linked to the clinical aggressiveness of upper tract urothelial carcinoma (UTUC). However, sitagliptin's impact on UTUC is poorly understood and requires further research.Patients and methods: This research utilized real-time PCR and immunohistochemistry to measure DPP4 mRNA and protein expression in UTUC. Sitagliptin's effects on cell proliferation and apoptosis were assessed using the alamarBlue assay and annexin V staining in UTUC cell lines. Migration ability was evaluated through wound-healing and transwell migration assays. The combined effect of sitagliptin and cisplatin on UTUC cell viability was also examined using both UTUC cell lines and patient-derived organoids.Results: Elevated DPP4 expression correlates with advanced tumor stages and reduced cancer-specific survival in UTUC. Sitagliptin treatment significantly reduced cell proliferation and enhanced apoptosis. Moreover, sitagliptin inhibited UTUC cell migration. Western blot results showed that sitagliptin treatment led to increased levels of apoptotic markers and reduced phosphorylation of AKT. It also influenced the phenotypical markers associated with epithelial-mesenchymal transition. Adding sitagliptin to cisplatin therapy did not show diminished antitumor efficacy compared with the effects of cisplatin alone.Conclusion: Sitagliptin inhibits the proliferation and migration of UTUC cells, promotes apoptosis, and influences the phenotypical transition from mesenchymal to epithelial states, likely via modulation of the AKT pathway. Sitagliptin may not cause chemotherapy resistance when combined with cisplatin treatment. These findings highlight its potential as an adjuvant therapy in UTUC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1001-1013"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17503

Takeshi Fujisawa, Hidehiro Hojo, Masaki Nakamura, Kenji Makita, Hidenari Hirata, Hidekazu Oyoshi, Kento Tomizawa, Yuzheng Zhou, Keiko Fukushi, Masafumi Ikeda, Sadamoto Zenda

{"title":"Clinical Outcomes of Patients Receiving Stereotactic Body Radiotherapy Dose De-escalation for Hepatocellular Carcinoma at the Hepatic Hilum.","authors":"Takeshi Fujisawa, Hidehiro Hojo, Masaki Nakamura, Kenji Makita, Hidenari Hirata, Hidekazu Oyoshi, Kento Tomizawa, Yuzheng Zhou, Keiko Fukushi, Masafumi Ikeda, Sadamoto Zenda","doi":"10.21873/anticanres.17503","DOIUrl":"https://doi.org/10.21873/anticanres.17503","url":null,"abstract":"Background/aim: Stereotactic body radiation therapy (SBRT) for centrally located hepatocellular carcinomas (HCCs) can cause severe central biliary toxicity. However, dose de-escalation SBRT has the potential to reduce biliary toxicity with excellent tumor control. Therefore, we aimed to retrospectively evaluate the efficacy and toxicity of de-escalated SBRT in patients with hepatic hilum HCC.Patients and methods: Patients diagnosed with peripherally located HCC received SBRT (40 Gy in five fractions), and those with centrally located HCC received de-escalated SBRT (35 Gy in five fractions) between January 2016 and August 2023 in National Cancer Center Hospital East.Results: Of the total 42 consecutive patients evaluated, 16 (38%) were diagnosed with centrally located HCC. The median observation time was 25 months (interquartile range=10-43). The 2-year cumulative incidences of local recurrence were 17.3% and 8.1% in patients with centrally and peripherally located HCC, respectively. No statistically significant differences were observed in the cumulative incidence of local recurrence, OS, or PFS between patients with centrally and peripherally located HCC. Univariate analysis of OS showed that a smaller clinical target volume of <20 ml was significantly associated with a better OS compared to a larger volume (p=0.017). No patient experienced grade 3 or higher treatment-related adverse events.Conclusion: Dose de-escalation SBRT for centrally located HCC showed good local control with no grade 3 or more RT related toxicities, suggesting it may be a safe alternative.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1159-1169"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17472

Yun-Chieh Wu, Min-Hsi Ku, Wei-Lun Huang, Luiza Dias, Chi-Wei Chen

{"title":"NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.","authors":"Yun-Chieh Wu, Min-Hsi Ku, Wei-Lun Huang, Luiza Dias, Chi-Wei Chen","doi":"10.21873/anticanres.17472","DOIUrl":"https://doi.org/10.21873/anticanres.17472","url":null,"abstract":"Nuclear enriched abundant transcript 1 (NEAT1), a long non-coding RNA (lncRNA), is a critical player in the pathogenesis and progression of ovarian cancer. Its abnormal expression in patients' follicular fluid (FF), granulosa cells, and oocytes has been linked to key processes such as cell proliferation, apoptosis, nuclear maturation, and follicle development. NEAT1's regulation of oocyte maturation and its influence on tumor dynamics and cellular communication within the FF is well-established. In the ovarian tumor microenvironment, NEAT1 contributes to cellular proliferation, invasion, chemoresistance, and apoptosis. Moreover, its dysregulation correlates with poor prognosis and increased tumor aggressiveness, underscoring its potential as a therapeutic target. The interaction of NEAT1 with miRNAs and signaling pathways further highlights its significant role in ovarian cancer progression and its potential as a biomarker. This review explores NEAT1's contributions to ovarian cancer progression, its influence within the follicular fluid microenvironment, and its therapeutic potential as a target to combat ovarian cancer development and drug resistance.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"825-842"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17508

Noriya Yamaguchi, Shuichi Morizane, Hiroshi Yamane, Ryutaro Shimizu, Ryoma Nishikawa, Yusuke Kimura, Katsuya Hikita, Kuniyasu Muraoka, Hirofumi Ono, Koji Ono, Masashi Honda, Atsushi Takenaka

{"title":"Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.","authors":"Noriya Yamaguchi, Shuichi Morizane, Hiroshi Yamane, Ryutaro Shimizu, Ryoma Nishikawa, Yusuke Kimura, Katsuya Hikita, Kuniyasu Muraoka, Hirofumi Ono, Koji Ono, Masashi Honda, Atsushi Takenaka","doi":"10.21873/anticanres.17508","DOIUrl":"https://doi.org/10.21873/anticanres.17508","url":null,"abstract":"Background/aim: Few studies have verified the relationship between treatment outcomes of robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC). This study aimed to compare the perioperative and oncologic outcomes between RARC and LRC.Patients and methods: Medical records of 75 patients (45 RARC and 30 LRC) who underwent radical cystectomy and standard or higher lymph node dissection between April 2013 and December 2019 at the Tottori University and other satellite hospitals were reviewed.Results: The operative time was shorter in the LRC group. Mean estimated blood loss was lower in the RARC group. No differences were noted in the complication rates. The mean number of lymph nodes removed was 23.1 in the RARC group and 13.9 in the LRC group (p<0.001). Cox proportional hazards regression analysis showed that the tumor variant of the transurethrally resected bladder tumor (TUR-BT) tissue (p=0.032) and lymph node metastasis (p= 0.041) were significantly associated with a higher risk of cancer-specific survival (CSS). No difference in the CSS (p= 0.337) and recurrence-free survival (p=0.448) was found in all patients having either RARC or LRC. However, the CSS of RARC was higher than that of LRC (p=0.032) in patients with locally advanced stages of bladder cancer such as pathological T stage ≥3 or pathological lymph node positivity.Conclusion: In patients with locally advanced bladder cancer pathological T stage ≥3 or pathological lymph node positivity, LRC appears to be associated with shorter CSS than RARC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1215-1224"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17492

Waqar Haque, Vivek Verma, Niva Mangalampalli, Mary R Schwartz, E Brian Butler, Kai Sun, Dharamvir Jain, Candy Arentz, Akshay Ramakrishnan, Bin S Teh

{"title":"Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.","authors":"Waqar Haque, Vivek Verma, Niva Mangalampalli, Mary R Schwartz, E Brian Butler, Kai Sun, Dharamvir Jain, Candy Arentz, Akshay Ramakrishnan, Bin S Teh","doi":"10.21873/anticanres.17492","DOIUrl":"https://doi.org/10.21873/anticanres.17492","url":null,"abstract":"Background/aim: The 21-gene assay recurrence score (RS) can guide the use of chemotherapy for the management of patients with pN0- 1 [1-3 positive lymph nodes (LNs)] breast cancer. However, practice patterns based on this assay, as well as associated outcomes, have not been evaluated for patients with pN2 (4-9 positive LNs) disease.Patients and methods: The National Cancer Database (NCDB) was queried for patients with newly-diagnosed, non-metastatic, hormone receptor-positive, Her2-negative, pN2 breast cancer who underwent adjuvant endocrine therapy and had a known RS. Kaplan-Meier analysis was used to evaluate overall survival (OS); Cox proportional hazards modeling determined variables associated with OS.Results: Of 1,658 patients, 1,109 (67%) received chemotherapy and 549 (33%) did not. Chemotherapy was administered to 54% of patients with a low-risk recurrence score (RS), 67% with intermediate-risk RS, and 75% with high-risk RS. Chemotherapy was associated with improved 5-year OS in low-risk RS (95.5% vs. 87.4%), intermediate-risk RS (91.9% vs. 83.5%), and high-risk RS (81.3% vs. 50.2%) (p≤0.001 for all). On Cox multivariable analysis, chemotherapy and the RS risk group significantly associated with OS (p<0.05 for both). Qualitatively, patients over 70 years of age appeared to benefit comparatively less from chemotherapy.Conclusion: Despite the underutilization of chemotherapy for hormone receptor-positive, Her2-negative, pN2 patients, it was associated with improved OS for all 21-gene panel risk groups. These results support the existing standard of chemotherapy for this population, although omission could be considered in patients over 70 years of age.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1055-1061"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Outcomes of Intraoperative Ventriculoperitoneal Shunt Clamping During Robotic-assisted Radical Prostatectomy: Retrospective Cohort Analysis.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17515

Jhe-Yuan Hsu, Hsien-Che Ou, Yen-Chuan Ou, Yi-Sheng Lin, Li-Hua Huang, Wei-Chun Weng, Chao-Yu Hsu, Min-Che Tung

{"title":"Safety and Outcomes of Intraoperative Ventriculoperitoneal Shunt Clamping During Robotic-assisted Radical Prostatectomy: Retrospective Cohort Analysis.","authors":"Jhe-Yuan Hsu, Hsien-Che Ou, Yen-Chuan Ou, Yi-Sheng Lin, Li-Hua Huang, Wei-Chun Weng, Chao-Yu Hsu, Min-Che Tung","doi":"10.21873/anticanres.17515","DOIUrl":"https://doi.org/10.21873/anticanres.17515","url":null,"abstract":"Background/aim: This study aimed to assess the safety and outcomes of intraoperative ventriculoperitoneal (VP) shunt clamping during robotic-assisted radical prostatectomy (RaRP) in patients with VP shunts.Patients and methods: A retrospective analysis of nine patients with VP shunts who underwent RaRP between February 2016 and October 2024 was conducted. Data on preoperative prostate-specific antigen (PSA) levels, surgical margins, complications, and follow-up durations were collected. Patients were stratified into subgroups based on PSA levels (≤10 vs. >10 ng/ml), operative time (<200 vs. ≥200 min), and estimated blood loss (<150 vs. ≥150 ml). Outcomes were analyzed using descriptive statistics, focusing on PSA trends, biochemical recurrence, and VP shunt functionality.Results: All procedures were completed without intraoperative or VP shunt-related complications. The median operative time was 180 min (range=180-330 min), and the median estimated blood loss was 170 ml (range=50-700 ml). Most patients showed significant PSA suppression, with a median PSA of <0.008 ng/ml at one year. Patients with initial PSA levels >10 ng/ml had greater variability in PSA trends, including persistent elevation or biochemical recurrence, whereas those with PSA levels ≤10 ng/ml had stable outcomes. No differences in oncological outcomes were noted based on operative time or blood loss. Median follow-up was 54 months (range=2-105 months).Conclusion: VP shunt clamping during RaRP is safe and effective, with favorable surgical and oncological outcomes and preserved shunt functionality. Larger studies are needed to confirm these findings and establish standardized protocols.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1281-1289"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-term Safety of Robot-assisted Rectal Surgery in Patients Aged ≥75 Years: A Single-center Retrospective Study.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17516

Fuminori Teraishi, Yusuke Yoshida, Ryohei Shoji, Nobuhiko Kanaya, Yuki Matsumi, Kunitoshi Shigeyasu, Yoshitaka Kondo, Shunsuke Kagawa, Toshiyoshi Fujiwara

{"title":"Short-term Safety of Robot-assisted Rectal Surgery in Patients Aged ≥75 Years: A Single-center Retrospective Study.","authors":"Fuminori Teraishi, Yusuke Yoshida, Ryohei Shoji, Nobuhiko Kanaya, Yuki Matsumi, Kunitoshi Shigeyasu, Yoshitaka Kondo, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"10.21873/anticanres.17516","DOIUrl":"https://doi.org/10.21873/anticanres.17516","url":null,"abstract":"Background/aim: The aging population challenges surgical management of rectal cancer. This study evaluated the short-term safety of robot-assisted rectal surgery (RARS) in patients aged 75 years and older, examining perioperative complications and surgical outcomes in this vulnerable population.Patients and methods: A single-center retrospective cohort study was conducted at Okayama University Hospital from September 2020 to December 2024, including 109 patients undergoing RARS. Patients were divided into older (≥75 years, n=19) and non-older (<75 years, n=90) groups. Surgical procedures utilized the da Vinci Xi system, with comprehensive assessment of perioperative characteristics and complications using the Clavien-Dindo classification.Results: The older group demonstrated significantly higher American Society of Anesthesiologists classification (89.5% ≥2 vs. 58.9% in non-older group, p=0.036). Postoperative complications were more frequent in the older group (8 vs. 18 cases, p=0.04), though severe complications were similar to those in the non-older group. Median postoperative hospital stay was longer in the older group (12 vs. 9 days, p=0.01), but this difference disappeared when excluding stoma cases. Critically, no postoperative mortality was observed within 30 days in either group.Conclusion: Robot-assisted rectal surgery appears safe for patients aged 75 years and older. While the older group experienced more complications, these were predominantly manageable. The findings suggest that careful patient selection and experienced surgical teams can successfully employ robotic techniques in older patients while maintaining oncological standards.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1291-1299"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiogenin-induced Osteoclastogenesis Mediates Bone Destruction in Oral Squamous Carcinoma.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17489

Kasumi Aoki, Nana Yoshitani, Naito Kurio, Norie Yoshioka, Jumpei Teramachi, Mika Ikegame, Hirohiko Okamura, Soichiro Ibaragi

{"title":"Angiogenin-induced Osteoclastogenesis Mediates Bone Destruction in Oral Squamous Carcinoma.","authors":"Kasumi Aoki, Nana Yoshitani, Naito Kurio, Norie Yoshioka, Jumpei Teramachi, Mika Ikegame, Hirohiko Okamura, Soichiro Ibaragi","doi":"10.21873/anticanres.17489","DOIUrl":"https://doi.org/10.21873/anticanres.17489","url":null,"abstract":"Background/aim: Bone destruction caused by oral cancer severely impacts patient quality of life. This study aimed to clarify the role of angiogenin (ANG) in osteoclastogenesis and oral cancer-induced bone destruction.Materials and methods: Recombinant ANG was used to assess its effects on osteoclast formation and bone resorption activity in bone marrow cultures. ANG-knockdown oral squamous carcinoma HSC-2 cells (ANG-RNAi) were transplanted into intramedullary cavities of femurs. Bone destruction was radiologically analyzed, while angiogenesis and osteoclast induction in the surrounding area of the transplanted lesion were histologically examined.Results: Recombinant ANG promoted osteoclast formation and bone resorption activity. Transplantation of ANG-RNAi cells significantly reduced tumor growth and bone destruction properties compared to transplantation of control cells. Histological analysis revealed lower angiogenesis and fewer osteoclast induction in the ANG-RNAi cells-transplanted group.Conclusion: ANG mediates oral cancer-induced bone destruction by promoting osteoclast formation and resorption. These findings suggest that ANG could be a potential therapeutic target for suppressing tumor growth, angiogenesis, and bone destruction in oral cancer therapy.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1025-1033"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knockdown of RFC2 Prevents the Proliferation, Migration and Invasion of Cervical Cancer Cells.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17486

Jae Woong Koh, Seon-Joo Park

{"title":"Knockdown of RFC2 Prevents the Proliferation, Migration and Invasion of Cervical Cancer Cells.","authors":"Jae Woong Koh, Seon-Joo Park","doi":"10.21873/anticanres.17486","DOIUrl":"https://doi.org/10.21873/anticanres.17486","url":null,"abstract":"Background/aim: Replication factor C subunit 2 (RFC2) is a component of the replication factor C (RFC) complex, which plays a critical role in DNA replication and repair. Recent studies have reported the involvement of RFC2 in several cancers. In this study, we investigated the functional role of RFC2 in cervical cancer progression.Materials and methods: RFC2 expression in cervical cancer cells was analyzed using quantitative real-time PCR (qRT-PCR) and western blotting. HeLa, ME-180, and SiHa cells were transfected with siRNAs targeting RFC2. Cell viability and proliferation were assessed using the MTT and colony formation assays, and cell cycle distribution was analyzed by flow cytometry. Migration and invasion abilities were evaluated through Transwell assays with or without Matrigel.Results: RFC2 knockdown significantly reduced cell proliferation in cervical cancer cells. Flow cytometry analysis revealed cell cycle arrest at the S phase. Additionally, RFC2 knockdown markedly inhibited the migration and invasion of cervical cancer cells. These results demonstrate the critical involvement of RFC2 in regulating proliferation and metastatic potential in cervical cancer cells.Conclusion: RFC2 plays a pivotal role in promoting cervical cancer progression by enhancing cell growth, regulating the cell cycle, and promoting metastatic behavior. Further studies on the molecular mechanisms of RFC2 in cancer-associated pathways may provide a novel therapeutic target for developing cervical cancer treatment strategies.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"989-1000"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer.

IF 1.6 4区医学

Anticancer research Pub Date : 2025-03-01 DOI: 10.21873/anticanres.17509

Teruhisa Sakamoto, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara, Tomoyuki Matsunaga, Manabu Yamamoto, Naruo Tokuyasu, Yoshiyuki Fujiwara

{"title":"Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer.","authors":"Teruhisa Sakamoto, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara, Tomoyuki Matsunaga, Manabu Yamamoto, Naruo Tokuyasu, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17509","DOIUrl":"https://doi.org/10.21873/anticanres.17509","url":null,"abstract":"Background/aim: The cachexia index (CXI) is a novel biomarker for cancer cachexia. Osteopenia is defined as low bone mineral density (BMD), which is closely associated with cancer cachexia. Osteopenia has received recent attention because of its association with survival outcomes in cancer. The aim of this study was to investigate the relationship between the CXI and BMD in combination as a prognosticator in patients with pancreatic cancer.Patients and methods: This study included 121 patients who had undergone pancreatectomy for pancreatic cancer. Data were retrospectively analyzed to evaluate the prognostic relationship between the CXI and BMD.Results: Five-year overall survival in the high CXI group was significantly better than that in the low CXI group (p= 0.004). Additionally, patients with osteopenia (i.e., low BMD) had significantly worse 5-year overall survival rates than patients without osteopenia (p=0.026). Multivariate analysis revealed that the CXI was an independent prognostic factor for patients with pancreatic cancer (p=0.020). Regarding the combination of the CXI and osteopenia, patients with both low CXI and osteopenia had a worse prognosis compared with patients with other combinations of the CXI and osteopenia (p=0.007). The area under the curve of the combination of the CXI and BMD to predict 5-year overall survival was greater than those of the CXI or BMD alone.Conclusion: There is a close prognostic relationship between the CXI and osteopenia in patients with pancreatic cancer, and patients with both a low CXI and osteopenia have low survival rates.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1225-1231"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0